Future studies should focus on evaluating bacterial clearance, challenges using natural infection routes, mucosal immune responses—particularly secretory IgA—and further optimization of epitope selection, adjuvants, and delivery systems to maximize vaccine efficacy and protective immunity. The gene discussed is CD79A; the disease is infection.